I direct the Clinical Trial Unit at the Cross Cancer Institute, a highly motivated team of investigators and experienced
staff that treats approximately 15% of our patients on cancer therapy trials. I am Executive Director of Translational Research in Oncology (www.trioncology.org), a global network of academic investigators testing new anticancer drug treatments. I serve on the steering committees of seven international drug trials.
I Chair the Alberta Pre-Phase 1 Cancer Program (www.prephaseone.com) that brings Alberta-made anticancer compounds to first-in-human testing,
with academic collaborators to bring their ideas to the clinic. My translational research program focuses on developing tests to predict which patients are most likely to benefit from anticancer therapy,
and exploiting novel targets and pathways to improve systemic cancer therapy.
My research program is funded by the Alberta Cancer Foundation, the Canadian Breast Cancer Research Alliance, the US Department of Defense, and multiple industry sponsors. Research Facilities and Affiliations
My primary academic appointment is in the Division of Medical Oncology in the Department of Oncology. I also hold a cross appointment in the Division of Experimental Oncology. Google Scholar Citations
Please click on this link for pubications, h-index and i10-indexhttp://scholar.google.com/citations?user=7jy6aWAAAAAJ&hl=en